4,7-dimethyl-5,6-dihydroxyindole | 80547-73-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,7-dimethyl-5,6-dihydroxyindole
• 英文别名: 4,7-dimethyl-indole-5,6-diol；4,7-Dimethyl-indol-5,6-diol；4,7-dimethyl-1H-indole-5,6-diol
• CAS: 80547-73-5
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: UYLXBDSHZSZAMY-UHFFFAOYSA-N

物化性质

• 熔点：
  170 °C
• 沸点：
  388.7±37.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  56.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4,5-三甲氧基-3,6-二甲基-苯乙基胺 在 水 、 氢溴酸 、 碳酸氢钠 、 potassium hexacyanoferrate(III) 作用下， 生成 4,7-dimethyl-5,6-dihydroxyindole
  参考文献：
  名称：

  708.黑色素及其前体。第七部分 甲基化5：6-二羟基吲哚，β-（4：5-二羟基-2-甲基苯基）丙氨酸和相关胺的合成

  摘要：

  DOI：

  10.1039/jr9530003525

文献信息

• Catechol O-methyltransferase. 12. Affinity labeling the active site with the oxidation products of 5,6-dihydroxyindole
  作者：Ronald T. Borchardt、Pramila Bhatia

  DOI：10.1021/jm00345a013

  日期：1982.3

  positions 4 or 7 on the aminochrome. Considering the number of potential electrophilic centers on the basic aminochrome structure, the site of the reaction might change depending on the aromatic substitution pattern. The preferred pathway of reaction may be determined in part by the juxtaposition of the protein nucleophile to the possible sites of attack on the electrophilic ligand but also in part on the

  已经合成了5,6-二羟基吲哚（5,6-DHI）和5,6-DHI的一系列4-和/或7-甲基化类似物并评估了它们灭活纯化的大鼠肝儿茶酚O-甲基转移酶（COMT）的能力）。通过从混合物的培养中排除氧气，可以防止这些试剂使COMT失活，这表明必须将其氧化为相应的氨基色素。底物保护研究和动力学研究表明，酶活性的损失是由于COMT活性位点上的关键氨基酸残基通过与醌型氧化产物反应而被修饰而引起的。5,6-DHI的4-和/或7-甲基化类似物的COMT抑制活性与涉及在氨基染料的4或7位发生1,4迈克尔加成反应的机理相反。考虑到基本氨基染料结构上潜在的亲电子中心的数量，反应的位置可能会根据芳族取代模式而变化。优选的反应途径可以部分由亲核蛋白与亲电子配体上可能的进攻位点的并置决定，也可以部分由亲电子位点的反应性决定，该反应性可能随芳香环上的取代而改变。
• USE OF NEURAL STEM CELLS FOR TREATMENT OF MALIGNANCY
  申请人：Crawford Susan E.

  公开号：US20140058184A1

  公开（公告）日：2014-02-27

  An improved method for treatment of malignancies is based on the interaction between nerve cells and angiogenesis of malignancies. In general, the method comprises: (1) harvesting neural stem cells; (2) culturing neural stem cells under conditions such that the cells proliferate while retaining their ability to differentiate; (3) applying a biocompatible adhesive to a post-surgical site of a malignancy; and (4) following the application of the biocompatible adhesive to the post-surgical site of the malignancy, applying the cultured neural stem cells to the post-surgical site of the malignancy to remove residual tumor cells and to induce endothelial cell apoptosis. The method can further comprise the administration of a therapeutically effective quantity of at least one anti-neoplastic therapeutic agent or administration of a therapeutically effective quantity of anti-neoplastic ionizing radiation. The invention further encompasses kits for use in treating malignancies.
• COATED PARTICLES FOR DRUG DELIVERY
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170266123A1

  公开（公告）日：2017-09-21

  In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more components, such as two pharmaceutically active agents or a pharmaceutically active agent and a major constituent of the core, having at least one dissimilar chemical or physical property (e.g., molecular weight, solubility, c Log P). In some such embodiments, placement of the uncoated core in certain environments results in the rapid release of a component (e.g., a pharmaceutically active agent) from and/or destabilization and breakdown of the core. In some embodiments, the biocompatible adhesive polymer in the coating acts as a molecular glue to stabilize the core and/or alter the release kinetics of at least one pharmaceutically active agent.
• US9637597B2
  申请人：——

  公开号：US9637597B2

  公开（公告）日：2017-05-02